Successful treatment of ulcerated infantile hemangioma with brimonidine-timolol cream: 2 cases report and review of the literature.

Ulceration is the most common complication of infantile hemangioma (IH). We reported two cases of ulcerated IH treated by new cream formulation of brimonidine 0.2%-timolol 0.5% (a combination of selective α-2-adrenergic agonist and nonselective β-blocker). In both cases, ulcerations were healed within 7-10 days after twice-daily application. No topical or systemic side effects were reported. In conclusion, brimonidine 0.2%-timolol 0.5% cream is a promising alternative in the topical treatment of ulcerated hemangiomas.